Table 3.

Analysis of non-endocrine morbidity of stereotactic radiosurgery (SRS)

Deficit	Complication rate for SRS@ (n = 104) % of patients sustaining specific complication (no. of events)	Median onset	Complication rate for MRI-guided SRS ± RT (n = 91) (October 1993–2015)	Complications for single MRI-guided SRS; no previous RT (n = 68) (October 1993–2015)	Factors associated with increased risk
Loss of visual acuity	5.8% (6)##	12 months (6–106)	2.2% (2)	0%	> 1 radiation treatment (p = 0.04)
Ophthalmoplegia	6.7% (7)##	24 months (2–78)	7.7% (7)	2.9% (2)	> 1 radiation treatment (p = 0.03)
Trigeminal Neuralgia	1% (1)	4 days	1.1% (1)	0	N/A
Stroke/TIA	2.9% (3)	83.5 months (47–105)	3.3% (3)	2.9% (2)	Similar incidence to that expected for age-sex matched population
Need for further intervention—Surgery	5.8% (6)	18 (8–68)	3.3% (3)	2.9% (2)
Need for further intervention—Radiation	2.9% (3)	78 (59–131)	N/A	N/A

^##Of those receiving a single MRI-guided SRS treatment and no fractionated radiotherapy there were no cases of visual loss and there were 2 cases of ophthalmoplegia

^@Incidence of any non-endocrine complication per patient year was 0.002 (26/13,937)